Daniel Kwon, MD
Assistant Professor
Medicine
School of Medicine

I am a physician-investigator. I care for patients with advanced cancer who are hospitalized and patients with genitourinary malignancies, such as prostate cancer. My research interests involve improving patient-centered outcomes for patients with cancer. This includes patient decision-making support, outcomes research, survivorship, cognition, and biomarkers. I use both qualitative and quantitative methods, as well as implementation science methods.

Awards

Show all (4) Hide

• GU ASCO Merit Award, 2021
• Rosenberg Endowed Fellowship, UCSF, 2020-2021
• GU ASCO Merit Award, 2020
• Alpha Omega Alpha, UCLA, 2015

Education & Training

Show all (5) Hide

• ASCO/AACR Methods in Clinical Cancer Research Workshop 2021
• Fellowship Hematology/Oncology UCSF 2021
• Residency Internal Medicine UCSF 2018
• M.D. UCLA 2015
• B.A. Molecular and Cell Biology UC Berkeley 2011

Interests

Show all (7) Hide

• Outcomes research
• Survivorship
• Genetic testing delivery
• Biomarkers
• Genitourinary cancer
• Shared decision-making
• Hospital based oncology

Grants and Projects

Show all (3) Hide

• Improving Informed Decision-Making for Precision Oncology in Veterans with Advanced Prostate Cancer, Department of Defense, 2022-2026
• MET-PAAM: Elucidating the molecular mechanisms of tumor progression in metastatic prostate cancer among men of African ancestry, Prostate Cancer Foundation, 2021-2023
• Consultation audio recordings to improve informed treatment decision-making in patients with advanced prostate cancer, Conquer Cancer/ANCO, 2021-2022

Publications (36)

Top publication keywords:
Carcinoma, NeuroendocrineCarcinoma, Small CellHepatectomyGerm CellsPiperazinesReferral and ConsultationGallium RadioisotopesPerioperative CareProstatic Neoplasms, Castration-ResistantNeuroendocrine TumorsProstatic NeoplasmsNitrilesAndrogen AntagonistsGenetic TestingPhthalazines

• Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
  JCO oncology practice 2023 Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M
• Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer.
  JCO oncology practice 2021 Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J
• Ethnic disparities among men with prostate cancer undergoing germline testing.
  Urologic oncology 2019 Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ
• Physician-reported barriers to referring cancer patients to specialists: prevalence, factors, and association with career satisfaction.
  Cancer 2014 Kwon DH, Tisnado DM, Keating NL, Klabunde CN, Adams JL, Rastegar A, Hornbrook MC, Kahn KL
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…

Show all (31 more) Hide

• Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
  eLife 2023 Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, …
• Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
  JAMA oncology 2023 Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, …
• FDG PET Scans in Cancer Care.
  JAMA oncology 2023 Litt HK, Kwon DH, Velazquez AI
• COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.
  Translational oncology 2023 Moey MYY, Hennessy C, French B, Warner JL, Tucker MD, Hausrath DJ, Shah DP, DeCara JM, Bakouny Z, Labaki C, Choueiri TK, Dent S, Akhter N, Ismail-Khan R, Tachiki L, Slosky D, Polonsky TS, Awosika JA, …
• Accuracy of Information Provided by ChatGPT Regarding Liver Cancer Surveillance and Diagnosis.
  AJR. American journal of roentgenology 2023 Cao JJ, Kwon DH, Ghaziani TT, Kwo P, Tse G, Kesselman A, Kamaya A, Tse JR
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
  medRxiv : the preprint server for health sciences 2023 Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, …
• Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects.
  European urology focus 2023 Kwon DH, Aggarwal RR
• Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
  JAMA oncology 2023 Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME…
• PSMA PET Scan.
  JAMA oncology 2022 Kwon DH, Velazquez AI, de Kouchkovsky I
• Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
  Urologic oncology 2022 Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ
• Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
  Cancers 2022 Wagner MJ, Hennessy C, Beeghly A, French B, Shah DP, Croessmann S, Vilar-Compte D, Ruiz-Garcia E, Ingham M, Schwartz GK, Painter CA, Chugh R, Fecher L, Park C, Zamulko O, Trent JC, Subbiah V, Khaki AR…
• Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
  Urologic oncology 2022 Kwon DH, Paciorek A, Zhang L, Borno HT, Bucknor M, Small EJ, Aggarwal RR
• Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
  Blood cancer discovery 2022 Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, …
• The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
  JNCI cancer spectrum 2022 Shah NJ, Patel VG, Zhong X, Pina L, Hawley JE, Lin E, Gartrell BA, Febles VA, Wise DR, Qin Q, Mellgard G, Joshi H, Nauseef JT, Green DA, Vlachostergios PJ, Kwon DH, Huang F, Liaw B, Tagawa S, Kantoff …
• COVID-19 outcomes in patients with cancer: Findings from the University of California health system database.
  Cancer medicine 2022 Kwon DH, Cadena J, Nguyen S, Chan KHR, Soper B, Gryshuk AL, Hong JC, Ray P, Huang FW
• Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.
  Open forum infectious diseases 2022 Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths…
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Reply to R. Kebudi et al.
  JCO oncology practice 2021 Tsu-Yu Wu J, Kwon DH, Glover M, Henry S, Wood D, Rubin D, Koshkin V, Schapira L, Shah SA
• Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
  European urology 2021 Kwon DH, Booth CM, Prasad V
• Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
  Cancer 2021 Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS
• Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW
• Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California.
  JCO oncology practice 2020 Wu JT, Kwon DH, Glover MJ, Henry S, Wood D, Rubin DL, Koshkin VS, Schapira L, Shah SA
• Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era.
  JCO oncology practice 2020 Kwon DH, Aggarwal RR, Esserman LJ, Belkora JK
• Does One Size Fit All? Re-evaluating Prostate-specific Antigen Progression Thresholds for Clinical Trials.
  European urology 2020 Kwon DH, Friedlander TW
• Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
  Urologic oncology 2020 Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small …
• A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer.
  Annals of translational medicine 2019 Kwon DH, Friedlander T
• Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
  Urologic oncology 2019 Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan…
• Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
  Pancreas 2019 Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K
• Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Veiseh M, Kwon DH, Borowsky AD, Tolg C, Leong HS, Lewis JD, Turley EA, Bissell MJ